MEDRx Co., Ltd.   Report issue

For profit Phase 3
Founded: Kagawa Japan (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2010
NCT01161615
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

IL Pharma | MEDRx USA, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

etodolac (lodine) (5 trials)

lidocaine (xylocaine) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ankle Injuries (Phase 3)

Back Pain (Phase 3)

Bursitis (Phase 3)

Low Back Pain (Phase 3)

Myalgia (Phase 3)

Shoulder Pain (Phase 3)

Sprains and Strains (Phase 3)

Tendinopathy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2